Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.

Expert Review of Gastroenterology & Hepatology
Mohamed SaidMagdi ElSerafy

Abstract

The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin. Changes in renal functions were compared across follow up time points (baseline, SVR4, and SVR8). Data on on-treatment adverse events (AEs), serious AEs, laboratory abnormalities, treatment discontinuation were collected. 171 patients were included (females 35%, mean age 53 years). 29 patients had liver cirrhosis. The most common etiologies of CKD were diabetes and/or hypertension (n = 67). All included patient reached the end of treatment (EOT) with no treatment discontinuations. The overall EOT response was 100%. 122/122 (100%) patients who reached 4 weeks post-treatment have achieved SVR4, and 80/80 (100%) have achieved SVR12. No reported SAEs. Ribavirin therapy was interrupted in 25% (43/171) of patients due to anemia; 16 patients required blood transfusions. The median eGFR improved from 33.5 (15) mL/min/1.73 m2 at baseline to 35 (36) mL/min/1.73 m2 at SVR8 (p = 0.0003). The use of ombitasvir, paritaprevir, and ritonavir for treatment of HCV-infec...Continue Reading

References

Aug 16, 2006·Annals of Internal Medicine·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
Dec 17, 2008·Gastroentérologie Clinique Et Biologique·V de Lédinghen, J Vergniol
Sep 13, 2013·The New England Journal of Medicine·Franco Dammacco, Domenico Sansonno
Nov 7, 2013·American Journal of Nephrology·David A GoodkinMichel Jadoul
Sep 27, 2016·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
May 4, 2017·Digestive Diseases·Sabela LensMaria-Carlota Londoño
Oct 12, 2017·The New England Journal of Medicine·Edward GaneFederico J Mensa
Sep 1, 2018·Clinics and Research in Hepatology and Gastroenterology·Mohamed A MekkyKhairy H Morsy
Sep 15, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·UNKNOWN AASLD-IDSA HCV Guidance Panel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.